Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Latest news

Sign up for updates
    • 24/10/2019
    • News

    Gábor Báthory speaks at the European Federation of Pharmacy Chains’ 1st International Conference on the future of pharmacy care

    On 17 October 2019, Van Bael & Bellis counsel Gábor Báthory spoke at the 1st International Conference on the future of pharmacy care organized by the European Federation of Pharmacy Chains in Prague. Topics covered at the conference included current issues and challenges of the European pharmacy sector such as ownership, quality, education of pharmaceutical professionals and innovation. Gábor's presentation discussed pharmacy ownership, with a focus on remedies available under EU Law against national restrictions on pharmacy ownership. Other speakers included Johan Wallér, CEO of the Swedish Pharmacy Association, Max Müller, Member of the Board at DocMorris, Europe’s largest internet pharmacy, Daniel Horák, CEO of Dr.Max, the largest pharmacy network in Slovakia and the Czech Republic, Peter Pažitný, Executive Director of the “CEE Health Policy Network” and former health policy advisor to various Ministers of Health of Slovakia, the Czech Republic and Hungary, and Tomas Sebek, Co-founder and Partner of uLékaře.cz, the Czech Republic’s leading virtual hospital. The Panel was moderated by Martin Dočkal, the founder and owner of APATYKÁŘ, the largest pharmacy website in the Czech Republic.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 03/12/2019
    • Articles

    EDPB Guidelines on Data Protection by Design and by Default

    On 13 November 2019, the European Data Protection Board (EDPB) published draft guidelines (the Guidelines) on the principle of “Data Protection by Design and by Default” set out under Article 25 of the General Data Protection Regulation (GDPR). The Guidelines explain how controllers must ensure that they effectively implement the “data protection principles and data subjects’ rights and freedoms by design and by default” during the design and life cycle of processing activities. The EDPB underlines that Data Protection by Design and Default is a requirement for all controllers, independent of their size. The examples contained in the Guidelines illustrate the broad range of processing activities to which this principle applies: from setting up membership administration to buying customer relationship management (CRM) software; designing online order forms; improving effectiveness of deliveries (through tracking employees); deciding on loan applications as a financial institution; or using artificial intelligence to profile customers. However, the complexity of implementing this principle will vary based on the individual processing operation. In this regard, the principle of Data Protection by Design and Default is coherent with the “risk-based approach” underlying the GDPR. Please click below for a short client memorandum on these guidelines.

    Read more
    • 28/11/2019
    • Articles

    European Commission Publishes State of Health in EU 2019 and Makes Policy Recommendations for Affordable Medicines

    The European Commission published today its Companion Report on the State of Health in the EU 2019 (see, attached – the “Report”) which forms the culmination of a cycle started in 2016 to develop expertise on performance assessments of the health systems in the Member States. The Report accordingly offers a number of general assessments of policy issues such as the decline in vaccination confidence, the digital transformation of health promotion and disease prevention and the requisite holistic approach in the quest for safe, effective and affordable medication. In addition, the Report also publishes key health findings for each of the 28 Member States. In a chapter entitled “Breaking down silos for safe, effective and affordable medicines”, the Report identifies four areas for Member States to focus on: • Building up Member State capacity to assess the value of medical technology – According to the Report, this implies greater cooperation among Member States, as this will bridge the information gap with suppliers. One channel for cooperation would be created by the proposed Health Technology Assessment Regulation which is currently under review by the EU political institutions. • Pooling knowledge and expertise regarding medicine pricing and procurement – The Report favours additional cooperation among and with the national competition authorities that built up expertise on excessive pricing cases and also maps the various forms of governmental cooperation on medicine procurement such as the Beneluxa and Valetta initiatives. • Maximising cost savings from generics and biosimilars – The Report notes that the uptake of these product categories is still unevenly spread across the EU. • Using medicines appropriately in hospitals – The Report calls for an update of best practices that date back to 2010.

    Read more
    • 28/11/2019
    • Newsletters

    VBB on Competition Law, Volume 2019, No. 11

    The November 2019 issue of our newsletter, VBB on Competition Law, which covers major developments in competition law at both the European Union and Member State levels.    Click below to view and download the issue

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.